<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Allergan Receives FDA Approval for Migraine Treatment
Image Overlay - Allergan Receives FDA Approval for Migraine Treatment

Allergan Receives FDA Approval for Migraine Treatment

January 9, 2020

Allergan Receives FDA Approval for Migraine Treatment

UBRELVY™ is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks. The therapy is taken by the user once a migraine starts — UBRELVY then provides relief for up to 24 hours. Yourway supports a patient-centric supply chain so that drugs in clinical trials can reach patients faster, regardless of where they are located.

Back to Index
Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Media

Articles

Case study: Coordinating a complex intercontinental shipment on a short timeline

Open chat
Come chat with us!
Hello! How can I help you?